ALIM Alimera Sciences Inc.

8.29
-0.12  -1%
Previous Close 8.41
Open 8.31
Price To Book -1.12
Market Cap 41,148,675
Shares 4,963,652
Volume 3,514
Short Ratio
Av. Daily Volume 71,880
Stock charts supplied by TradingView

NewsSee all news

  1. Almira Sciences, Inc 13D filing

    CHICAGO, Dec. 11, 2019 /PRNewswire/ -- Ronald L Chez, a private investor, files a 13D for Alimera Sciences, Inc. (NASDAQ:ALIM). Alimera returns to growth in the 3rd quarter and expects continued progress in the 4th

  2. Alimera Sciences to Participate in the LD Micro 12th Annual Main Event on December 10, 2019

    ATLANTA, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or "Company"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of

  3. Alimera Announces Regulatory Approval for ILUVIEN® in Benelux Countries for The Treatment of Non-Infectious Posterior Uveitis

    Company continues to execute on its international expansion strategy ATLANTA, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of

  4. Alimera Sciences to Participate in the 31st Annual Piper Jaffray Healthcare Conference

    ATLANTA, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or "Company"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of

  5. Alimera Sciences Announces Effectiveness of Previously Announced Reverse Stock Split

    ATLANTA, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014
Iluvien
Diabetic macular edema

Latest News

  1. Almira Sciences, Inc 13D filing

    CHICAGO, Dec. 11, 2019 /PRNewswire/ -- Ronald L Chez, a private investor, files a 13D for Alimera Sciences, Inc. (NASDAQ:ALIM). Alimera returns to growth in the 3rd quarter and expects continued progress in the 4th

  2. Alimera Sciences to Participate in the LD Micro 12th Annual Main Event on December 10, 2019

    ATLANTA, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or "Company"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of

  3. Alimera Announces Regulatory Approval for ILUVIEN® in Benelux Countries for The Treatment of Non-Infectious Posterior Uveitis

    Company continues to execute on its international expansion strategy ATLANTA, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of

  4. Alimera Sciences to Participate in the 31st Annual Piper Jaffray Healthcare Conference

    ATLANTA, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or "Company"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of

  5. Alimera Sciences Announces Effectiveness of Previously Announced Reverse Stock Split

    ATLANTA, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

  6. Alimera Sciences Terminates Equity Purchase Agreement

    ATLANTA, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

  7. Alimera Sciences Announces Board's Approval of Reverse Stock Split Ratio

    ATLANTA, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

  8. Alimera Sciences to Participate in the 10th Annual Craig-Hallum Alpha Select Conference in New York

    ATLANTA, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or "Company"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of

  9. Alimera Sciences Announces Third Quarter 2019 Financial Results and Provides Corporate Update

    Third Quarter and Recent Company Highlights: Consolidated Net Revenue Up 16% Compared to Third Quarter 2018International Net Revenue Up 62% Compared to Third Quarter 2018Launch of ILUVIEN® for Non-Infectious Posterior

  10. Alimera Obtains Marketing Authorization for ILUVIEN® in Portugal for the Treatment of Non-Infectious Posterior Uveitis

    ATLANTA, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

  11. Alimera Sciences Announces Top Line Revenue Expectation For the Third Quarter of 2019

    ATLANTA, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

  12. Alimera Sciences Announces Clinical Data Featuring the Benefits of ILUVIEN® to be Presented at the American Academy of Ophthalmology Annual Meeting

    ATLANTA, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

  13. Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN® in Benelux Countries

    ATLANTA, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

  14. Alimera Sciences Board of Directors Approves Reverse Stock Split and 10b5-1 Stock Purchase Plan for U.S. Executive Management

    ATLANTA, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

  15. Alimera Sciences Launches ILUVIEN® in Germany For Non-Infectious Uveitis Indication

    ATLANTA, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal